Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment, often leaving patients with long-term pain and functional challenges. With limited therapeutic options and fragmented care, it remains a significant clinical challenge. The session “Chemotherapy-induced Peripheral Neuropathy (CIPN): From Bench to Bedside,” presented by Drs. Jijun Xu, Charles Argoff, and Jianguo Cheng at PainConnect, offers a much-needed exploration of the latest advancements in CIPN management.
What to Expect
This multidisciplinary session dives into both foundational research and clinical applications for CIPN care. Attendees will benefit from the expertise of physician-scientists sharing cutting-edge insights on:
- Molecular Mechanisms: Understanding CIPN’s underlying causes, with a focus on targeting the spinal cord and dorsal root ganglion (DRG) for innovative treatments.
- Guidelines and Treatments: A detailed review of the latest ASCO guidelines and evidence-based pharmacological and nonpharmacological therapies.
- Emerging Strategies: Exploring innovative interventions such as scrambler therapy, cryotherapy, compression techniques, and neuromuscular training.
Why It Matters
CIPN doesn’t just affect patients—it can disrupt cancer treatment, forcing dose reductions or cessation. By providing a comprehensive overview, this session empowers clinicians to close critical gaps in CIPN care. From groundbreaking research to practical applications, attendees will gain actionable tools to improve patient outcomes and quality of life.
Interactive case discussions and Q&A opportunities ensure attendees can apply these insights to their own practice, creating a bridge from the lab to clinical care.
Don’t miss this chance to stay at the forefront of CIPN management. Join PainConnect, the AAPM annual meeting and equip yourself with the knowledge to transform care for patients living with chemotherapy-induced neuropathy.
Register now and make an impact where it matters most!
